Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first-line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy
Berdeja, Jesus G., Bauer, Todd, Arrowsmith, Edward, Essell, James, Murphy, Patrick, Reeves, James A., Boccia, Ralph V., Donnellan, William, Flinn, IanVolume:
177
Language:
english
Journal:
British Journal of Haematology
DOI:
10.1111/bjh.14536
Date:
April, 2017
File:
PDF, 405 KB
english, 2017